Based on the Pressure Biosciences Inc stock forecast from 0 analysts, the average analyst target price for Pressure Biosciences Inc is not available over the next 12 months. Pressure Biosciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Pressure Biosciences Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Pressure Biosciences Inc’s stock price was USD 0.015. Pressure Biosciences Inc’s stock price has changed by +7.14% over the past week, -45.45% over the past month and -92.11% over the last year.
No recent analyst target price found for Pressure Biosciences Inc
No recent average analyst rating found for Pressure Biosciences Inc
Company Overview Pressure Biosciences Inc
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products. The company also provides pain relief, skincare solutions, personal wellness, athletic recovery, and specialized pet care products. It serves researchers at academic laboratories, government agencies, biotechnology and pharmaceutical companies, other life science institutions, and food/beverages laboratories. The company has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. Pressure BioSciences, Inc. was incorporated in 1978 and is headquartered in Canton, Massachusetts. Read Less
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based su...Read More
Frequently Asked Questions About Pressure Biosciences Inc (PBIO) Stock
Stock Target Advisor's fundamental analysis for Pressure Biosciences Inc's stock is Very Bearish.
Unfortunately we do not have enough data on PBIO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBIO's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PBIO's stock to indicate if its overvalued.
The last closing price of PBIO's stock was USD 0.02.
The most recent market capitalization for PBIO is USD 0.52M.
Unfortunately we do not have enough analyst data on PBIO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pressure Biosciences Inc's stock.
As per our most recent records Pressure Biosciences Inc has 15 Employees.
Pressure Biosciences Inc's registered address is 480 Neponset Street, Canton, MA, United States, 02021.
You can get more information about it from Pressure Biosciences Inc's website at https://www.pressurebiosciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Pressure Biosciences Inc (PBIO) Stock
Stock Target Advisor's fundamental analysis for Pressure Biosciences Inc's stock is Very Bearish.
Unfortunately we do not have enough data on PBIO's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PBIO's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PBIO's stock to indicate if its overvalued.
The last closing price of PBIO's stock was USD 0.02.
The most recent market capitalization for PBIO is USD 0.52M.
Unfortunately we do not have enough analyst data on PBIO's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pressure Biosciences Inc's stock.
As per our most recent records Pressure Biosciences Inc has 15 Employees.
Pressure Biosciences Inc's registered address is 480 Neponset Street, Canton, MA, United States, 02021.
You can get more information about it from Pressure Biosciences Inc's website at https://www.pressurebiosciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
